Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the regulation of lipid metabolism, energy production, and inflammation. It is well established that all of the three isoforms of PPARs expressed in the cardiomyocytes, and that PPARs are closely involved in the regulation of lipid metabolism and energy homeostasis as well as many other different aspects in the heart. We think that PPARs are very important therapeutic targets for drug development, however, the drugs targeting at PPARs meet some trouble in clinical practice, especially the reported side effects related to heart failure. This review summarizes different functions and mechanisms of each isoform in cardiac hypertrophy and heart failure, for the reason that if more efforts are made to investigate the interactions among different isoforms, minimize the off-target effects, and avoid PPARs-independent side effects, we can develop safer and more effective PPAR agonists for the clinical practice in the near future.
Keywords: Peroxisome proliferator-activated receptors, PPARs, cardiac hypertrophy, heart failure.
Current Pharmaceutical Design
Title:The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Volume: 23 Issue: 11
Author(s): Hai-Han Liao, Xu-Hui Jia, Huang-Jun Liu, Zheng Yang and Qi-Zhu Tang*
Affiliation:
- Department of Cardiology, Renmin Hospital of Wuhan University; Cardiovascular Research Institute, Wuhan University at Jiefang Road 238, Wuhan 430060,China
Keywords: Peroxisome proliferator-activated receptors, PPARs, cardiac hypertrophy, heart failure.
Abstract: Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the regulation of lipid metabolism, energy production, and inflammation. It is well established that all of the three isoforms of PPARs expressed in the cardiomyocytes, and that PPARs are closely involved in the regulation of lipid metabolism and energy homeostasis as well as many other different aspects in the heart. We think that PPARs are very important therapeutic targets for drug development, however, the drugs targeting at PPARs meet some trouble in clinical practice, especially the reported side effects related to heart failure. This review summarizes different functions and mechanisms of each isoform in cardiac hypertrophy and heart failure, for the reason that if more efforts are made to investigate the interactions among different isoforms, minimize the off-target effects, and avoid PPARs-independent side effects, we can develop safer and more effective PPAR agonists for the clinical practice in the near future.
Export Options
About this article
Cite this article as:
Liao Hai-Han, Jia Xu-Hui, Liu Huang-Jun, Yang Zheng and Tang Qi-Zhu*, The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612822666160928150040
DOI https://dx.doi.org/10.2174/1381612822666160928150040 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Cellular Senescence During Vascular Calcification: A Key Paradigm in Aging Research
Current Aging Science Pharmacology of TRP Channels in the Vasculature
Current Vascular Pharmacology Relevance of Anxiety and Depression in Chronic Obstructive Pulmonary Disease (COPD)
Current Respiratory Medicine Reviews Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Neural Control of Blood Pressure: Focusing on Capsaicin-Sensitive Sensory Nerves
Cardiovascular & Hematological Disorders-Drug Targets Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay
Current Drug Targets Gene Therapy for Familial Hypercholesterolemia
Current Pharmaceutical Design Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Mitochondrial Mutations in Atherosclerosis: New Solutions in Research and Possible Clinical Applications
Current Pharmaceutical Design Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
Current Drug Targets 24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes
Current Hypertension Reviews Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer
Current Pharmaceutical Design The Influence of Fatty Acids on Metoprolol - Human Serum Albumin Interaction in Low Affinity Binding Sites: A Multifactorial NMR Approach
Protein & Peptide Letters Marine Peptides for Preventing Metabolic Syndrome
Current Protein & Peptide Science Pharmacological Therapy in Children with Atrial Fibrillation and Atrial Flutter
Current Pharmaceutical Design The Use of Infliximab in Dermatology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Method Development & Validation of LCMS/MS for Atorvastatin and Olmesartan in Human Plasma to Trace Drug Interaction of Formulation
Current Pharmaceutical Analysis